Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new drug last month and ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...

With every new year comes reflection and resolutions. But as we go to press well into January, it is worth a reminder that studies show nearly 90% ...